| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
|
Thanarajasingam, Gita
|
|
2018
|
5 |
11 |
p. e563-e598
|
artikel
|
| 2 |
Biosimilars: when a negative study can be positive
|
Link, Brian K
|
|
2018
|
5 |
11 |
p. e500-e501
|
artikel
|
| 3 |
Changing views on adverse event reporting
|
Flores, Beatriz
|
|
2018
|
5 |
11 |
p. e506-e507
|
artikel
|
| 4 |
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
|
Ogura, Michinori
|
|
2018
|
5 |
11 |
p. e543-e553
|
artikel
|
| 5 |
Elastic compression therapy to prevent post-thrombotic syndrome
|
Labropoulos, Nicos
|
|
2018
|
5 |
11 |
p. e494-e495
|
artikel
|
| 6 |
Embracing the complexity in cancer therapy
|
The Lancet Haematology,
|
|
2018
|
5 |
11 |
p. e493
|
artikel
|
| 7 |
Exercise training: a prescription for sickle-cell disease?
|
Kato, Gregory J
|
|
2018
|
5 |
11 |
p. e502-e503
|
artikel
|
| 8 |
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
|
Popat, Uday R
|
|
2018
|
5 |
11 |
p. e532-e542
|
artikel
|
| 9 |
Histological transformation and secondary malignancies in follicular lymphoma
|
Vitolo, Umberto
|
|
2018
|
5 |
11 |
p. e496-e497
|
artikel
|
| 10 |
Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis
|
Amin, Elham E
|
|
2018
|
5 |
11 |
p. e512-e519
|
artikel
|
| 11 |
Is pharmacokinetic guidance a must in busulfan regimens?
|
Kanda, Yoshinobu
|
|
2018
|
5 |
11 |
p. e498-e499
|
artikel
|
| 12 |
Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complications (EXDRE): an open-label randomised controlled trial
|
Gellen, Barnabas
|
|
2018
|
5 |
11 |
p. e554-e562
|
artikel
|
| 13 |
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
|
Watanabe, Takashi
|
|
2018
|
5 |
11 |
p. e520-e531
|
artikel
|
| 14 |
Real-world evidence in safety assessment of new treatments
|
Smedby, Karin E
|
|
2018
|
5 |
11 |
p. e510-e511
|
artikel
|
| 15 |
The cost of cure
|
Schmiegelow, Kjeld
|
|
2018
|
5 |
11 |
p. e504-e505
|
artikel
|
| 16 |
The need to assess financial adverse events
|
Nastoupil, Loretta J
|
|
2018
|
5 |
11 |
p. e508-e509
|
artikel
|
Tijdschrift beschrijving